Skip to main content
Clinical Trials/NCT02168283
NCT02168283
Withdrawn
Phase 4

Treatment of Asymptomatic Fluid Overload in Peritoneal Dialysis Patients

Chinese University of Hong Kong1 site in 1 countryDecember 2015

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Chronic Kidney Disease
Sponsor
Chinese University of Hong Kong
Locations
1
Primary Endpoint
blood pressure control
Status
Withdrawn
Last Updated
6 years ago

Overview

Brief Summary

INTRODUCTION Peritoneal dialysis (PD) is a life-saving treatment for end-stage renal disease patients. However, cardiovascular disease remains the major cause of morbidity and mortality in PD patients. It is now realized that chronic asymptomatic intravascular hypervolemia is an important cause of cardiovascular disease in PD patients.

OBJECTIVES To determine the effects of treating asymptomatic fluid overload on blood pressure, hospitalization and cardiovascular morbidity in PD patients.

HYPOTHESIS The investigators hypothesize that treating asymptomatic fluid overload could improve the clinical outcome of PD patients.

DESIGN & SUBJECTS This is an open label randomized control trial. The investigators plan to recruit 60 PD patients with asymptomatic fluid overload, defined as overhydration (OH) ≥ 2 liters. Patients will be randomized to active fluid management (treatment arm) or conventional management (control arm).

STUDY INSTRUMENTS Overhydration will be identified by bioimpedance spectroscopy.

INTERVENTIONS For the treatment arm, active fluid management includes dietary counseling, diuretics, and intensive dialysis regimen. For the control arm, patients will only receive dietary counseling. Patients will be followed for one year.

MAIN OUTCOME MEASURES Blood pressure control, number of hospital admission and duration of hospitalization for all cause, and hospitalization for cardiovascular disease during the study period.

DATA ANALYSIS Blood pressure control will be compared by Student's t test. Hospitalization data will be compared by non-parametric Mann Whitney U test.

EXPECTED RESULTS The study will determine the benefit of treating asymptomatic fluid overload in PD patients.

Detailed Description

The investigators plan to recruit 60 PD patients with asymptomatic fluid overload, which is defined as overhydration (OH) ≥ 2 liters as measured by bioimpedance spectroscopy. Patients with clinical symptoms of fluid overload (including, but not restricted to, dyspnea on exertion, peripheral edema, pulmonary congestion) will be excluded. The investigators will also exclude patients who are in overt pulmonary edema and required urgent medical care, who have cognitive impairment or problem of communication, unlikely to survive for more than three months, have mechanical problems of the dialysis catheter, or have active peritonitis or peritoneal failure.

Registry
clinicaltrials.gov
Start Date
December 2015
End Date
September 2018
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Cheuk-Chun SZETO

Professor

Chinese University of Hong Kong

Eligibility Criteria

Inclusion Criteria

  • asymptomatic fluid overload, defined as overhydration (OH) ≥ 2 liters as measured by bioimpedance spectroscopy

Exclusion Criteria

  • clinical symptoms of fluid overload (including, but not restricted to, dyspnea on exertion, peripheral edema, pulmonary congestion)
  • overt pulmonary edema and required urgent medical care
  • cognitive impairment or problem of communication
  • unlikely to survive for more than three months
  • mechanical problems of the dialysis catheter
  • active peritonitis or peritoneal failure

Outcomes

Primary Outcomes

blood pressure control

Time Frame: 1 year

hospitalization for cardiovascular disease

Time Frame: 1 year

number of antihypertensive medications

Time Frame: 1 year

duration of hospitalization for all cause

Time Frame: 1 year

Secondary Outcomes

  • degree of overhydration(1 year)
  • nutritional status(1 year)
  • arterial pulse wave velocity(1 year)
  • change in residual GFR(1 year)
  • all-cause mortality(1 year)
  • cardiovascular mortality(1 year)

Study Sites (1)

Loading locations...

Similar Trials